Cardiac disorders as risk factors for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 20, Issue 3, 2010, Pages 749-763

  De Toledo Ferraz Alves, Tânia Corrêa ^a,b   Ferreira, Luiz Kobuti ^a   Wajngarten, Mauricio ^a   Busatto, Geraldo F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ABC Region Medical School   (Brazil)

Author keywords

Aging; Alzheimer's disease; dementia; vascular risk factors

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOENZYME; APOLIPOPROTEIN E; CYANOCOBALAMIN; FOLIC ACID; GLYCOGEN SYNTHASE KINASE 3; HOMOCYSTEINE; METHOTREXATE; N ACETYLASPARTIC ACID; PROTEIN KINASE C; PYRIDOXINE; REACTIVE OXYGEN METABOLITE;

ADRENAL CORTEX ATROPHY; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; APOPTOSIS; ATHEROSCLEROSIS; BRAIN ATHEROSCLEROSIS; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN FUNCTION; BRAIN PERFUSION; BRAIN SIZE; BRAIN VENTRICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CELL ACTIVATION; CENTRAL GRAY MATTER; CIGARETTE SMOKING; CINGULATE GYRUS; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYANOCOBALAMIN DEFICIENCY; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EXPOSURE; EXCITOTOXICITY; FOLIC ACID DEFICIENCY; FRONTAL CORTEX; GENETIC ASSOCIATION; GRAY MATTER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART SURGERY; HIPPOCAMPUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; KIDNEY FAILURE; MEDITERRANEAN DIET; MILD COGNITIVE IMPAIRMENT; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PYRIDOXINE DEFICIENCY; REVIEW; STROKE; SUBICULUM; THROMBOEMBOLISM; WHITE MATTER;

EID: 77954547550     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091561     Document Type: Review

References (214)

1. Bottino CM, Azevedo D, Jr., Tatsch M, Hototian SR, Moscoso MA, Folquitto J, Scalco AZ, Bazzarella MC, Lopes MA, Litvoc J (2008) Estimate of dementia prevalence in a community sample from Sao Paulo, Brazil. Dement Geriatr Cogn Disord 26, 291-299.
2. Scazufca M, Menezes PR, Vallada HP, Crepaldi AL, Pastor- Valero M, Coutinho LM, Di Rienzo VD, Almeida OP (2008) High prevalence of dementia among older adults from poor socioeconomic backgrounds in Sao Paulo, Brazil. Int Psychogeriatr 20, 394-405.
3. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB (2007) Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125-132.
4. Rocchi A, Orsucci D, Tognoni G, Ceravolo R, Siciliano G (2009) The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr Alzheimer Res 6, 224-237.
5. Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 107, 139-146. (Pubitemid 36070946)
6. Newman AB, Arnold AM, Naydeck BL, Fried LP, Burke GL, Enright P, Gottdiener J, Hirsch C, O'Leary D, Tracy R (2003) "Successful aging": effect of subclinical cardiovascular disease. Arch Intern Med 163, 2315-2322. (Pubitemid 37310192)
7. Rosendorff C, Beeri MS, Silverman JM (2007) Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol 16, 143-149.
8. Viswanathan A, Rocca WA, Tzourio C (2009) Vascular risk factors and dementia: how to move forward? Neurology 72, 368-374.
9. Erkinjuntti T, Gauthier S (2009) The concept of vascular cognitive impairment. Front Neurol Neurosci 24, 79-85.
10. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66, 300-305.
11. Middleton LE, Yaffe K (2009) Promising strategies for the prevention of dementia. Arch Neurol 66, 1210-1215.
12. Reitz C,TangMX,Manly J, Mayeux R, Luchsinger JA(2007) Hypertension and the risk of mild cognitive impairment. Arch Neurol 64, 1734-1740. (Pubitemid 350254935)
13. Chiang CJ, Yip PK, Wu SC, Lu CS, Liou CW, Liu HC, Liu CK, Chu CH, Hwang CS, Sung SF, Hsu YD, Chen CC, Liu SI, Yan SH, Fong CS, Chang SF, You SL, Chen CJ (2007) Midlife risk factors for subtypes of dementia: a nested casecontrol study in Taiwan. Am J Geriatr Psychiatry 15, 762-771.
14. Skoog I, Gustafson D (2006) Update on hypertension and Alzheimer's disease. Neurol Res 28, 605-611.
15. Connelly PJ, Prentice NP, Fowler KG (2005) Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 20, 623-628.
16. Luchsinger JA, Mayeux R (2004) Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 6, 261-266. (Pubitemid 39359464)
17. Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ (2002) Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging study. Stroke 33, 26-30.
18. Elias MF (1998) Effects of chronic hypertension on cognitive functioning. Geriatrics 53 Suppl 1, S49-52.
19. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145. (Pubitemid 126512042)
20. Farmer ME, Kittner SJ, Abbott RD, Wolz MM, Wolf PA, White LR (1990) Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study. J Clin Epidemiol 43, 475-480.
21. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB (2003) Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 27, 260-268.
22. Chen X, Wen W, Anstey KJ, Sachdev PS (2006) Effects of cerebrovascular risk factors on gray matter volume in adults aged 60-64 years: a voxel-based morphometric study. Psychiatry Res 147, 105-114.
23. Korf ES,Wahlund LO, Visser PJ, Scheltens P (2004) Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 63, 94-100.
24. Raz N, Rodrigue KM, Haacke EM (2007) Brain aging and its modifiers: insights from in vivo neuromorphometry and susceptibility weighted imaging. Ann N Y Acad Sci 1097, 84-93.
25. Wiseman RM, Saxby BK, Burton EJ, Barber R, Ford GA, O'Brien JT (2004) Hippocampal atrophy, whole brain volume, and white matter lesions in older hypertensive subjects. Neurology 63, 1892-1897.
26. Korf ES, White LR, Scheltens P, Launer LJ (2004) Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 44, 29-34.
27. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM (2008) Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 39, 349-354.
28. Peters R, Beckett N (2009) Hypertension, dementia, and antihypertensive treatment: implications for the very elderly. Curr Hypertens Rep 11, 277-282.
29. Purandare N (2009) Preventing dementia: role of vascular risk factors and cerebral emboli. Br Med Bull 91, 49-59.
30. Paglieri C, Bisbocci D, Caserta M, Rabbia F, Bertello C, Canade A, Veglio F (2008) Hypertension and cognitive function. Clin Exp Hypertens 30, 701-710.
31. Peters R, Beckett N, Forette F, Tuomilehto J, Ritchie C,Walton I, Waldman A, Clarke R, Poulter R, Fletcher A, Bulpitt C (2009) Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. Int Psychogeriatr 21, 359-368.
32. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545-551.
33. Luchsinger JA, Reitz C, Patel B,Tang MX,Manly JJ, Mayeux R (2007) Relation of diabetes to mild cognitive impairment. Arch Neurol 64, 570-575. (Pubitemid 46588347)
34. XuW, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2009) Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58, 71-77.
35. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, Craft S (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66, 315-322.
36. Launer LJ (2009) Diabetes: vascular or neurodegenerative: an epidemiologic perspective. Stroke 40, S53-55.
37. Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P (2006) Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 77, 304-307.
38. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L (2009) Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 52, 1031-1039.
39. Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192.
40. Last D, Alsop DC, Abduljalil AM, Marquis RP, de Bazelaire C, Hu K, Cavallerano J, Novak V (2007) Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care 30, 1193-1199.
41. Wessels AM, Simsek S, Remijnse PL, Veltman DJ, Biessels GJ, Barkhof F, Scheltens P, Snoek FJ, Heine RJ, Rombouts SA (2006) Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 49, 2474-2480.
42. Kumar A, Haroon E, Darwin C, Pham D, Ajilore O, Rodriguez G, Mintz J (2008) Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging 27, 14-19.
43. den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, Breteler MM (2003) Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46, 1604-1610.
44. Korf ES, White LR, Scheltens P, Launer LJ (2006) Brain aging in very old men with type 2 diabetes: the Honolulu- Asia Aging Study. Diabetes Care 29, 2268-2274.
45. Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Hennen J, Renshaw PF, Jacobson AM (2006) Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 55, 326-333.
46. Inoue T, Fushimi H, Yamada Y, Udaka F, Kameyama M (1996) Asymptomatic multiple lacunae in diabetics and nondiabetics detected by brain magnetic resonance imaging. Diabetes Res Clin Pract 31, 81-86.
47. Tiehuis AM, van der Graaf Y, Visseren FL, Vincken KL, Biessels GJ, Appelman AP, Kappelle LJ, Mali WP(2008) Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 39, 1600-1603.
48. Taguchi A (2009) Vascular factors in diabetes and Alzheimer's disease. J Alzheimers Dis 16, 859-864.
49. Lee J, Kim MS (2007) The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract 77 Suppl 1, S49-57.
50. Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S (2000) Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm 107, 1201-1212.
51. Hernandez F, de Barreda EG, Fuster-MatanzoA, Goni-Oliver P, Lucas JJ, Avila J (2009) The role of GSK3 in Alzheimer disease. Brain Res Bull 80, 248-250.
52. Mendes CT, Mury FB, de Sa Moreira E, Alberto FL, Forlenza OV, Dias-Neto E, Gattaz WF (2009) Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry Clin Neurosci 259, 16-22.
53. Swan GE, Lessov-Schlaggar CN (2007) The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev 17, 259-273.
54. Anstey KJ, von Sanden C, Salim A, O'Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166, 367-378.
55. Jha P (2009) Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer 9, 655-664.
56. Kelly TN, Gu D, Chen J, Huang JF, Chen JC, Duan X,Wu X, Chen CS, He J (2008) Cigarette smoking and risk of stroke in the chinese adult population. Stroke 39, 1688-1693.
57. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2003) Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34, 392-396. (Pubitemid 36206336)
58. Brody AL, Mandelkern MA, Jarvik ME, Lee GS, Smith EC, Huang JC, Bota RG, Bartzokis G, London ED (2004) Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol Psychiatry 55, 77-84.
59. Gallinat J, Meisenzahl E, Jacobsen LK, Kalus P, Bierbrauer J, Kienast T, Witthaus H, Leopold K, Seifert F, Schubert F, Staedtgen M (2006) Smoking and structural brain deficits: a volumetric MR investigation. Eur J Neurosci 24, 1744-1750.
60. Longstreth WT, Jr., Arnold AM, Manolio TA, Burke GL, Bryan N, Jungreis CA, O'Leary D, Enright PL, Fried L (2000) Clinical correlates of ventricular and sulcal size on cranial magnetic resonance imaging of 3,301 elderly people. The Cardiovascular Health Study. Collaborative Research Group. Neuroepidemiology 19, 30-42.
61. Longstreth WT, Jr., Diehr P, Manolio TA, Beauchamp NJ, Jungreis CA, Lefkowitz D (2001) Cluster analysis and patterns of findings on cranial magnetic resonance imaging of the elderly: the Cardiovascular Health Study. Arch Neurol 58, 635-640.
62. Almeida OP, Garrido GJ, Lautenschlager NT, Hulse GK, Jamrozik K, Flicker L (2008) Smoking is associated with reduced cortical regional gray matter density in brain regions associated with incipient Alzheimer disease. Am J Geriatr Psychiatry 16, 92-98.
63. Abrous DN, Adriani W, Montaron MF, Aurousseau C, Rougon G, Le Moal M, Piazza PV (2002) Nicotine selfadministration impairs hippocampal plasticity. J Neurosci 22, 3656-3662.
64. Oliveira-da-Silva A, Vieira FB, Cristina-Rodrigues F, Filgueiras CC, Manhaes AC, Abreu-Villaca Y (2009) Increased apoptosis and reduced neuronal and glial densities in the hippocampus due to nicotine and ethanol exposure in adolescent mice. Int J Dev Neurosci 27, 539-548.
65. Gallinat J, Lang UE, Jacobsen LK, Bajbouj M, Kalus P, von Haebler D, Seifert F, Schubert F (2007) Abnormal hippocampal neurochemistry in smokers: evidence from proton magnetic resonance spectroscopy at 3 T. J Clin Psychopharmacol 27, 80-84.
66. Tyas SL, White LR, Petrovitch H,Webster Ross G, Foley DJ, Heimovitz HK, Launer LJ (2003) Mid-life smoking and latelife dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 24, 589-596.
67. Zambroski CH (2003) Qualitative analysis of living with heart failure. Heart Lung 32, 32-40.
68. Zuccala G, Pedone C, Cesari M, Onder G, Pahor M, Marzetti E, Lo Monaco MR, Cocchi A, Carbonin P, Bernabei R (2003) The effects of cognitive impairment on mortality among hospitalized patients with heart failure. Am J Med 115, 97-103.
69. Almeida OP, Flicker L (2001) The mind of a failing heart: a systematic reviewof the association between congestive heart failure and cognitive functioning. Intern Med J 31, 290-295.
70. Antonelli Incalzi R, Trojano L, AcanforaD, CrisciC, Tarantino F, Abete P, Rengo F (2003) Verbal memory impairment in congestive heart failure. J Clin Exp Neuropsychol 25, 14-23.
71. Ackerman RH (2001) Cerebral blood flow and neurological change in chronic heart failure. Stroke 32, 2462-2464.
72. Gruhn N, Larsen FS, Boesgaard S, Knudsen GM, Mortensen SA, Thomsen G, Aldershvile J (2001) Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 32, 2530-2533. (Pubitemid 33055301)
73. Alves TC, Rays J, Fraguas R, Jr.,Wajngarten M, Meneghetti JC, Prando S, Busatto GF (2005) Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-HMPAO SPECT. J Neuroimaging 15, 150-156.
74. Vogels RL, Oosterman JM, van Harten B, Gouw AA, Schroeder-Tanka JM, Scheltens P, van der Flier WM, Weinstein HC (2007) Neuroimaging and correlates of cognitive function among patients with heart failure. Dement Geriatr Cogn Disord 24, 418-423.
75. Vogels RL, van der Flier WM, van Harten B, Gouw AA, Scheltens P, Schroeder-Tanka JM, Weinstein HC (2007) Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 9, 1003-1009.
76. Bennett SJ, Sauve MJ (2003) Cognitive deficits in patients with heart failure: a review of the literature. J Cardiovasc Nurs 18, 219-242.
77. Deary IJ, Capewell S, Hajducka C, Muir AL (1991) The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study. Br J Clin Pharmacol 32, 347-353.
78. Glynn LM, Christenfeld N, Gerin W (2002) The role of rumination in recovery from reactivity: cardiovascular consequences of emotional states. Psychosom Med 64, 714-726.
79. Grubb NR, Fox KA, Smith K, Best J, Blane A, Ebmeier KP, Glabus MF, O'Carroll RE(2000) Memory impairment in outof- hospital cardiac arrest survivors is associated with global reduction in brain volume, not focal hippocampal injury. Stroke 31, 1509-1514.
80. Almeida OP, Tamai S (2001) Congestive heart failure and cognitive functioning amongst older adults. Arq Neuropsiquiatr 59, 324-329.
81. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A, Panza F (2006) Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 364, 91-112. (Pubitemid 43120631)
82. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V (2006) Lipid metabolism in cognitive decline and dementia. Brain Res Rev 51, 275-292. (Pubitemid 44183829)
83. Mortimer JA, Snowdon DA, Markesbery WR (2009) The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord 23, 152-157.
84. Bookheimer S, Burggren A (2009) APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol 5, 343-362.
85. Xu G, McLaren DG, Ries ML, Fitzgerald ME, Bendlin BB, Rowley HA, Sager MA, Atwood C, Asthana S, Johnson SC (2009) The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain 132, 383-391.
86. Wharton SB, O'Callaghan JP, Savva GM, Nicoll JA, Matthews F, Simpson JE, Forster G, Shaw PJ, Brayne C, Ince PG (2009) Population variation in glial fibrillary acidic protein levels in brain ageing: relationship to Alzheimer-type pathology and dementia. Dement Geriatr Cogn Disord 27, 465-473.
87. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A (2008) Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 12, 2762-2771.
88. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima- Costa MF (2008) Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the Bambui Health Aging Study (BHAS). Braz J Med Biol Res 41, 89-94.
89. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP (2008) NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70, 17-24.
90. Sawada H, Udaka F, Izumi Y, Nishinaka K, Kawakami H, Nakamura S, Kameyama M (2000) Cerebral white matter lesions are not associated with apoE genotype but with age and female sex in Alzheimer's disease. J Neurol Neurosurg Psychiatry 68, 653-656.
91. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR, Jr., Weiner MW (2009) MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132, 1067-1077.
92. Mueller SG, Schuff N, Raptentsetsang S, Elman J, Weiner MW(2008) Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T. Neuroimage 42, 42-48.
93. Honea RA, Vidoni E, Harsha A, Burns JM (2009) Impact of APOE on the healthy aging brain: A voxel-based MRI and DTI study. J Alzheimers Dis, 18, 553-564.
94. Hiekkanen H, Kurki T, Brandstack N, Kairisto V, Tenovuo O (2007) MRI changes and ApoE genotype, a prospective 1- year follow-up of traumatic brain injury: a pilot study. Brain Inj 21, 1307-1314.
95. Isoniemi H, Kurki T, Tenovuo O, Kairisto V, Portin R (2006) Hippocampal volume, brain atrophy, and APOE genotype after traumatic brain injury. Neurology 67, 756-760. (Pubitemid 44394184)
96. Espeseth T, Greenwood PM, Reinvang I, Fjell AM, Walhovd KB, Westlye LT, Wehling E, Lundervold A, Rootwelt H, Parasuraman R (2006) Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. Cogn Affect Behav Neurosci 6, 31-43.
97. Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, Burke GL, Tracy R, Bhadelia R (1998) Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 29, 388-398.
98. Espeseth T,Westlye LT, Fjell AM,Walhovd KB, Rootwelt H, Reinvang I (2008) Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol Aging 29, 329-340.
99. Wisdom NM, Callahan JL, Hawkins KA (2009) The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. Neurobiol Aging, in press.
100. Glatt SJ, Chayavichitsilp P, Depp C, Schork NJ, Jeste DV (2007) Successful aging: from phenotype to genotype. Biol Psychiatry 62, 282-293.
101. Lee BK, Glass TA, Wand GS, McAtee MJ, Bandeen-Roche K, Bolla KI, Schwartz BS (2008) Apolipoprotein e genotype, cortisol, and cognitive function in community-dwelling older adults. Am J Psychiatry 165, 1456-1464.
102. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM (2006) Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29. (Pubitemid 43739586)
103. Smelt AH, de Beer F (2004) Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Semin Vasc Med 4, 249-257.
104. Mooijaart SP, van Vliet P, van Heemst D, Rensen PC, Berbee JF, Jolles J, de Craen AJ, Westendorp RG (2007) Plasma levels of apolipoprotein E and cognitive function in old age. Ann N Y Acad Sci 1100, 148-161. (Pubitemid 47092647)
105. Kandiah N, Feldman HH (2009) Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci 283, 230-234.
106. Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P (2006) Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 185, 78-86.
107. Stankovic G, Sparks DL (2006) Change in circulating Creactive protein is not associated with atorvastatin treatment in Alzheimer's disease. Neurol Res 28, 621-624.
108. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y(2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302, 627-637.
109. Diaz-Arrastia R (2000) Homocysteine and neurologic disease. Arch Neurol 57, 1422-1427.
110. Refsum H, Ueland PM, Nygard O, Vollset SE (1998) Homocysteine and cardiovascular disease. Annu Rev Med 49, 31-62.
111. Nurk E, Refsum H, Tell GS, Engedal K, Vollset SE, Ueland PM, Nygaard HA, Smith AD (2005) Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann Neurol 58, 847-857.
112. Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A, 3rd (2005) High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr 82, 627-635.
113. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 29, 1-11.
114. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483. (Pubitemid 34441738)
115. Sachdev PS (2005) Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry 29, 1152-1161.
116. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H (2002) Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 58, 1539-1541.
117. Seshadri S, Wolf PA, Beiser AS, Selhub J, Au R, Jacques PF, Yoshita M, Rosenberg IH, D'Agostino RB, DeCarli C (2008) Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 65, 642-649.
118. den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM(2003) Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126, 170-175. (Pubitemid 36068567)
119. Chee MW, Chen KH, Zheng H, Chan KP, Isaac V, Sim SK, Chuah LY, SchuchinskyM, Fischl B, Ng TP (2009) Cognitive function and brain structure correlations in healthy elderly East Asians. Neuroimage 46, 257-269.
120. Williams JH, Pereira EA, Budge MM, Bradley KM (2002) Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people. Age Ageing 31, 440-444.
121. Kim SR, Choi SH, Ha CK, Park SG, Pyun HW, Yoon DH (2009) Plasma Total Homocysteine Levels are not Associated with Medial Temporal Lobe Atrophy, but with White Matter Changes in Alzheimer's Disease. J Clin Neurol 5, 85-90.
122. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300, 1774-1783.
123. Balk EM, Raman G, Tatsioni A, Chung M, Lau J, Rosenberg IH (2007) Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med 167, 21-30.
124. Clarke RJ, Bennett DA (2008) B vitamins for prevention of cognitive decline: insufficient evidence to justify treatment. JAMA 300, 1819-1821.
125. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
126. Evin G, Weidemann A (2002) Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. Peptides 23, 1285-1297.
127. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45-53.
128. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70, 1664-1671.
129. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65, 256-263.
130. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM,Koudstaal PJ, BretelerMM(2004) Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55, 570-575.
131. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM(2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660.
132. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362.
133. Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P (2009) Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 73, 847-853.
134. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A 105, 14052-14057.
135. Okereke OI, Xia W, Selkoe DJ, Grodstein F (2009) Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 66, 1247-1253.
136. Bhatia R, Lin H, Lal R (2000) Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J 14, 1233-1243.
137. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171.
138. ArendashGW, Su GC, Crawford FC, Bjugstad KB, MullanM (1999) Intravascular beta-amyloid infusion increases blood pressure: implications for a vasoactive role of beta-amyloid in the pathogenesis of Alzheimer's disease. Neurosci Lett 268, 17-20.
139. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C (2002) Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283, H315-323. (Pubitemid 34705353)
140. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M,Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M (1999) Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 96, 14088-14093.
141. Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin T, Chen J (2000) Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 21, 207-214.
142. Ettorre E, Cicerchia M, De Benedetto G, Fossati C, Guglielmi S, Manzon L, Servello A, Petrillo A, Marigliano V (2009) A possible role of atrial fibrillation as a risk factor for dementia. Arch Gerontol Geriatr 49 Suppl 1, 71-76.
143. Bellomo A, Mancinella M, Troisi G, Marigliano V (2009) [Relationship between atrial fibrillation and other cardiovascular risk factors in Alzheimer's disease. New prevention opportunities]. Recenti Prog Med 100, 124-126.
144. Demarin V, Kes VB, Morovic S, Zavoreo I (2009) Evaluation of aging vs dementia by means of neurosonology. J Neurol Sci 283, 9-12.
145. Purnell C, Gao S, Callahan CM, Hendrie HC (2009) Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord 23, 1-10.
146. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A (1997) Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28, 316-321. (Pubitemid 27096997)
147. Breteler MM, Claus JJ, Grobbee DE, Hofman A (1994) Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 308, 1604-1608.
148. Hogue CW, Jr., Hershey T, Dixon D, Fucetola R, Nassief A, Freedland KE, Thomas B, Schechtman K (2006) Preexisting cognitive impairment inwomen before cardiac surgery and its relationship with C-reactive protein concentrations. Anesth Analg 102, 1602-1608; table of contents.
149. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ (1995) The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 274, 1846-1851.
150. Rosengart TK, Sweet J, Finnin EB,Wolfe P, Cashy J, Hahn E, Marymont J, Sanborn T (2005) Neurocognitive functioning in patients undergoing coronary artery bypass graft surgery or percutaneous coronary intervention: evidence of impairment before intervention compared with normal controls. Ann Thorac Surg 80, 1327-1334; discussion 1334-11325
151. Koschack J, Irle E (2005) Small hippocampal size in cognitively normal subjects with coronary artery disease. Neurobiol Aging 26, 865-871.
152. Soneira CF, Scott TM (1996) Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin Anat 9, 118-127.
153. Sparks DL, Hunsaker JC, 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR (1990) Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11, 601-607.
154. Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC, 3rd (1993) Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol 52, 135-142.
155. Ernest CS, Murphy BM,Worcester MU, Higgins RO, Elliott PC, Goble AJ, Le Grande MR, Genardini N, Tatoulis J (2006) Cognitive function in candidates for coronary artery bypass graft surgery. Ann Thorac Surg 82, 812-818.
156. Jensen BO, Hughes P, Rasmussen LS, Pedersen PU, Steinbruchel DA (2006) Cognitive outcomes in elderly high-risk patients after off-pump versus conventional coronary artery bypass grafting: a randomized trial. Circulation 113, 2790-2795. (Pubitemid 44305290)
157. Millar K, Asbury AJ, Murray GD (2001) Pre-existing cognitive impairment as a factor influencing outcome after cardiac surgery. Br J Anaesth 86, 63-67.
158. Selnes OA, Grega MA, Bailey MM, Pham LD, Zeger SL, Baumgartner WA, McKhann GM (2009) Do management strategies for coronary artery disease influence 6-year cognitive outcomes? Ann Thorac Surg 88, 445-454.
159. Silbert BS, Scott DA, Evered LA, Lewis MS, Maruff PT (2007) Preexisting cognitive impairment in patients scheduled for elective coronary artery bypass graft surgery. Anesth Analg 104, 1023-1028.
160. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA (2001) Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 344, 395-402.
161. Selnes OA, Royall RM, Grega MA, Borowicz LM, Jr., Quaskey S, McKhann GM (2001) Cognitive changes 5 years after coronary artery bypass grafting: is there evidence of late decline? Arch Neurol 58, 598-604.
162. Lee TA, Wolozin B, Weiss KB, Bednar MM (2005) Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheimers Dis 7, 319-324.
163. Selnes OA, Grega MA, Borowicz LM, Jr., Royall RM, McKhann GM, Baumgartner WA (2003) Cognitive changes with coronary artery disease: a prospective study of coronary artery bypass graft patients and nonsurgical controls. Ann Thorac Surg 75, 1377-1384.
164. Hogue CW, Jr., Palin CA, Arrowsmith JE (2006) Cardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth Analg 103, 21-37.
165. van Dijk D, Spoor M, Hijman R, Nathoe HM, Borst C, Jansen EW, Grobbee DE, de Jaegere PP, Kalkman CJ (2007) Cognitive and cardiac outcomes 5 years after off-pump vs on-pump coronary artery bypass graft surgery. JAMA 297, 701-708.
166. Ong CT, Sung KC, Sung SF,Wu CS, Hsu YC, Su YH (2009) Impact of silent infarction on the outcome of stroke patients. J Formos Med Assoc 108, 224-230.
167. Longstreth WT, Jr., Dulberg C, Manolio TA, Lewis MR, Beauchamp NJ, Jr., O'Leary D, Carr J, Furberg CD (2002) Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 33, 2376-2382.
168. de laTorre JC (2006)Howdo heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 28, 637-644.
169. Knopman DS, Mosley TH, Catellier DJ, Coker LH (2009) Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement 5, 207-214.
170. Curiati PK, Tamashiro JH, Squarzoni P, Duran FL, Santos LC, Wajngarten M, Leite CC, Vallada H, Menezes PR, Scazufca M, Busatto GF, Alves TC (2009) Brain structural variability due to aging and gender in cognitively healthy Elders: results from the Sao Paulo Ageing and Health study. AJNR Am J Neuroradiol 30, 1850-1856.
171. de la Torre JC (2008) Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 5, 126-132.
172. Cechetto DF, Hachinski V, Whitehead SN (2008) Vascular risk factors and Alzheimer's disease. Expert Rev Neurother 8, 743-750.
173. Staekenborg SS, Koedam EL, Henneman WJ, Stokman P, Barkhof F, Scheltens P, van der FlierWM(2009) Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 40, 1269-1274.
174. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
175. Das SK, Bose P, Biswas A, Dutt A, Banerjee TK, Hazra AM, Raut DK, Chaudhuri A, Roy T (2007) An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 68, 2019-2026.
176. DeCarli C, Miller BL, Swan GE, Reed T,Wolf PA, Carmelli D (2001) Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 58, 643-647.
177. Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH (2003) Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol 60, 1394-1399. (Pubitemid 37248800)
178. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 56, 1683-1689.
179. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M(2007) Serum cholesterol changes after midlife and late-life cognition: twentyone- year follow-up study. Neurology 68, 751-756.
180. RileyKP, SnowdonDA, MarkesberyWR(2002) Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 51, 567-577.
181. Gabryelewicz T, Styczynska M, Luczywek E, Barczak A, Pfeffer A, Androsiuk W, Chodakowska-Zebrowska M, Wasiak B, Peplonska B, Barcikowska M (2007) The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int J Geriatr Psychiatry 22, 563-567.
182. Forti P, Maioli F, Pisacane N, Rietti E, Montesi F, Ravaglia G (2007) Atrial fibrillation and risk of dementia in nondemented elderly subjects with and without mild cognitive impairment (MCI). Arch Gerontol Geriatr 44 Suppl 1, 155-165.
183. Debette S, Bombois S, Bruandet A, Delbeuck X, Lepoittevin S, Delmaire C, Leys D, Pasquier F (2007) Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke 38, 2924-2930.
184. Wolf H, Ecke GM, Bettin S, Dietrich J, Gertz HJ (2000) Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. Int J Geriatr Psychiatry 15, 803-812.
185. van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR, Jr., DeCarli C (2008) Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 255, 1302-1308.
186. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66, 216-225.
187. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33, 1152-1162.
188. de la Torre JC (2000) Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 21, 331-342.
189. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3, 184-190.
190. Aliev G, Smith MA, de la Torre JC, Perry G (2004) Mitoch ondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4, 649-663.
191. de la Torre JC (1997) Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann N Y Acad Sci 826, 75-91.
192. de la Torre JC (2002) Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 977, 196-215.
193. de la Torre JC (1999) Critical threshold cerebral hypoperfusion causes Alzheimer's disease? Acta Neuropathol 98, 1-8.
194. Menon U, Kelley RE (2009) Subcortical ischemic cerebrovascular dementia. Int Rev Neurobiol 84, 21-33.
195. Bangen KJ, Delano-Wood L, Wierenga CE, McCauley A, Jeste DV, Salmon DP, Bondi MW (2009) Associations between stroke risk and cognition in normal aging and Alzheimer's disease with and without depression. Int J Geriatr Psychiatry 25, 175-182.
196. Kumar-Singh S (2008) Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. Genes Brain Behav 7 Suppl 1, 67-82.
197. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T,Wester HJ, Kurz A, Drzezga A (2009) Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65, 927-934.
198. Esler WP, Marshall JR, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW, Maggio JE (2002) Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: mechanistic implications for apoE4 enhanced amyloid burden and risk for Alzheimer's disease. Amyloid 9, 1-12.
199. Farkas E, De Jong GI, Apro E, De Vos RA, Steur EN, Luiten PG (2000) Similar ultrastructural breakdown of cerebrocortical capillaries in Alzheimer's disease, Parkinson's disease, and experimental hypertension. What is the functional link? Ann N Y Acad Sci 903, 72-82.
200. Farkas E, Donka G, de Vos RA, Mihaly A, Bari F, Luiten PG (2004) Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol (Berl) 108, 57-64.
201. Woo MA, Macey PM, Fonarow GC, Hamilton MA, Harper RM (2003) Regional brain gray matter loss in heart failure. J Appl Physiol 95, 677-684.
202. Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109, 813-836.
203. Jellinger KA (2005) Understanding the pathology of vascular cognitive impairment. J Neurol Sci 229-230, 57-63.
204. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A, Robbins J (2004) Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 101, 10132-10136.
205. Yasojima K, McGeer EG, McGeer PL (2001) Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 919, 115-121.
206. Wisniewski T, Ghiso J, Frangione B(1997) Biology of Abeta amyloid in Alzheimer's disease. Neurobiol Dis 4, 313-328.
207. Yuan Q, Zuo X, Jia J (2009) Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among Northern Chinese Han. Neurosci Lett 457, 133-136.
208. Krsteska R (2009) Risk factors for dementia of the Alzheimer and vascular type. Med Pregl 62, 201-206.
209. de la Torre JC (2000) Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord 14 Suppl 1, S72-81.
210. Kuczynski B, JagustW, Chui HC, Reed B (2009) An inverse association of cardiovascular risk and frontal lobe glucose metabolism. Neurology 72, 738-743.
211. Rowe JW, Kahn RL (1987) Human aging: usual and successful. Science 237, 143-149.
212. Raz N, Rodrigue KM (2006) Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev 30, 730-748.
213. Knopman DS, Mosley TH, Catellier DJ, Sharrett AR (2005) Cardiovascular risk factors and cerebral atrophy in a middleaged cohort. Neurology 65, 876-881.
214. Gianaros PJ, Greer PJ, Ryan CM, Jennings JR (2006) Higher blood pressure predicts lower regional grey matter volume: Consequences on short-term information processing. Neuroimage 31, 754-765.